Consensus CSL Limited

Stocks

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 04:10:08 09/07/26 pm AEST			5-day change	1st Jan Change
125.53 ^AUD	+0.99%		+6.05%	-27.29%

08/07	Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine	RE
03/07	Australian shares log best week in 3 as Fed-hike bets cool; banks, miners lead	RE

Evolution of the Average Target: CSL Limited

Evolution of the Target Price: CSL Limited

Changes in Analyst Recommendations: CSL Limited

e883ce8ab769d4f798.EU6Qpoq8m0sJQChb7F3ajNSmszeByrL9zjy494Yyn3o.dgvU6P_G6idMBR89hiSc7pDH61zUhtaZiXHAvORI6RVIH93K7f6uD34jYQ~ea147ead6ba646d3df488f25865dea30

Analysts' recommendations: CSL Limited

25/06	CSL, Plasma Industry Could Continue to Grow Strongly for Considerable Period, Jefferies Says	MT
12/05	CSL's Fiscal-Year Earnings Guidance Downgrade Not Surprising, Jefferies Says	MT
20/03	CSL's Business Not Threatened by CIDP Therapy Competition, Says Jefferies	MT
02/03	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
11/02	CSL's Fiscal H1 EBIT Boosted by Cost Reductions, Jarden Says	MT
09/12	CSL's China Albumin Sale to Improve in Fiscal H2 2026, Says Jefferies	MT
11/11	CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies	MT
07/11	CSL Expected to See Potential Medium-Term Earnings Upside, Says Jefferies	MT
07/11	CSL's Horizon 2 Approach to 'Significantly' Boost Margins, Earnings, Jarden Says	MT
29/10/25	Jarden Research Adjusts CSL's Price Target to AU$287.14 from AU$304.17, Keeps at Overweight	MT
29/10/25	CSL Faces Macroeconomic Challenges, Will Take Time to Rerate, Says Jefferies, Shares Down 3%	MT
28/10/25	Canaccord Genuity Upgrades CSL to Buy from Hold; Price Target is AU$225	MT
28/10/25	CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says	MT
02/10/25	CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies	MT
01/08/25	Carlisle Faces Downgrade From Loop Capital; Shares Fall	MT
11/07/25	CSL Shares Fall Amid Target Price Cut by Morgans Financial	MT
10/07/25	Morgans Financial Upgrades CSL to Buy from Add; Price Target is AU$303.70	MT
25/10/24	CSL's R&D Day "Uninspiring," Jarden Research Says	MT
09/09/24	CSL 'Strong Franchise in Medium Term' Amid Higher Fiscal 2024 Earnings, Jefferies Says	MT
05/09/24	Carlisle Expected to Show Solid Growth, Margin Expansion, Oppenheimer Says	MT
14/08/24	Jarden Research Adjusts CSL's Price Target to AU$329.62 From AU$305.34, Keeps at Overweight	MT
06/03/24	Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight	MT
14/02/24	Jarden Research CSL’s Price Target to AU$296.02 From AU$298.57, Keeps at Overweight	MT
13/02/24	Jarden Research Adjusts CSL’s Price Target to AU$298.57 From AU$316.16, Keeps at Overweight	MT
03/11/22	Arcturus Therapeutics Shares Rise 31% After Vaccine Collaboration	DJ

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CSL LIMITED					+12.47%
	REGENERON PHARMACEUTICALS, INC.					+24.08%
	UCB					+15.78%
	SAMSUNG BIOLOGICS CO.,LTD.					+50.88%
	BIOGEN INC.					+11.22%
	MODERNA, INC.					-35.1%
	INCYTE CORPORATION					-4.95%
	INNOVENT BIOLOGICS, INC.					+36.43%
	SWEDISH ORPHAN BIOVITRUM AB					+2.54%
	BRIDGEBIO PHARMA, INC.					+30.82%
	Average					+14.42%
	Weighted average by Cap.					+16.32%